ArticlemBio2025
A U508C synonymous mutation in the SARS-CoV-2 deletion hotspot reduces deletion frequency and accelerates viral clearance.
Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A deletion hotspot within the non-structural protein 1 (NSP1) gene (locus 500-532) has been observed in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomes analyzed by next-generation sequencing. Deletions in the hotspot have been previously reported to suppress interferon-β expression, suggesting that they constitute a conserved mechanism for SARS-CoV-2 evasion of the immune response. In this study, we introduced a synonymous mutation (U508C) into the SARS-CoV-2 genome using a reverse genetics system. This mutation disrupts both direct and inverted repeat motifs within the deletion hotspot, resulting in a significant reduction in deletion frequency. Furthermore, the clinically isolated U508C mutant strain also exhibited a markedly reduced frequency of deletions compared with the closely related strain from the same lineage, similar to the mutants we generated by reverse genetics. Structural predictions revealed that the wild-type RNA in this region forms a loosely unwound structure, while the RNA with the U508C mutation adopts a more stable structure due to the formation of nine intra-strand base pairs. This increased stability likely reduces polymerase slippage, a major contributor to deletions. Although the U508C mutant replicated as well as that of the wild-type virus in human bronchial epithelial Calu-3 cells, its clearance from the culture supernatant was significantly accelerated. This study provides valuable insights into the intricate interplay between viral RNA structure and viral pathogenesis. Understanding how RNA structural modifications influence viral behavior has broad implications for the development of novel antiviral strategies, including RNA-targeted therapeutics and attenuated virus for vaccine development.IMPORTANCEThis study focuses on a specific region, termed the "deletion hotspot," in the SARS-CoV-2 genome where deletions frequently occur and enable the virus to evade the immune response. In this study, we found that the introduction of a U508C synonymous mutation within this deletion hotspot significantly reduced the frequency of deletions, probably because it changed the structure of the viral RNA, stabilizing it and thereby reducing replication errors. While the mutant virus replicated at a similar rate to that of the original virus in cultured cells, its rate of clearance from the culture medium was significantly increased, suggesting that the mutation may have weakened the virus. This study underscores the importance of understanding how the structure of viral RNA influences viral behavior. Such knowledge could inform the development of novel antiviral drugs and strategies for combatting viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.